MINNEAPOLIS, Nov. 13, 2014 /PRNewswire/ -- Uroplasty,
Inc. (NASDAQ: UPI) a medical device company that develops,
manufactures and markets innovative proprietary products for the
treatment of voiding dysfunctions, today announced that it will
participate in the Canaccord Genuity 2014 Medical Technology &
Diagnostics Forum on Thursday, November 20.
Rob Kill, President and CEO, will
present at 4:00pm ET and meet with
investors one on one at the conference at the Westin Grand Central
in New York City. Attendance at
the conference is by invitation only. A live webcast of the
presentation with accompanying slides will be broadcast via the
Internet. Those interested in joining the webcast may access it
through Uroplasty's website at www.uroplasty.com. An archived
replay of the presentation will be available for 90 days following
the event.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered
in Minnetonka, Minnesota, with
wholly-owned subsidiaries in the
Netherlands and the United
Kingdom, is a global medical device company that develops,
manufactures and markets innovative proprietary products for the
treatment of voiding dysfunctions. Our focus is the continued
commercialization of our Urgent® PC Neuromodulation System, which
is the only commercially available, FDA-cleared system that
delivers percutaneous tibial nerve stimulation (PTNS) for the
office-based treatment of overactive bladder (OAB). OAB is a
chronic condition that affects approximately 42 million U.S.
adults. The symptoms include urinary urgency, frequency and
urge incontinence. We also offer Macroplastique®, an injectable
urethral bulking agent for the treatment of adult female stress
urinary incontinence primarily due to intrinsic sphincter
deficiency. For more information on the Company and its products,
please visit Uroplasty, Inc. at www.uroplasty.com.
For Further Information:
Uroplasty, Inc.
Brett Reynolds, SVP and CFO
952-426-6152
EVC Group
Doug Sherk (Investors)
415-652-9100
Janine McCargo (Media)
646-688-0425
SOURCE Uroplasty, Inc.